论文部分内容阅读
目的评价长春瑞宾为主的联合化疗诱导治疗Ⅲ期非小细胞肺癌的疗效和毒副作用。方法３。例初 治病人均经细胞学或病理学证实的Ⅲ期非小细胞肺癌，采用 ＮＩＰ方案：ＮＶＢ ２５ ｍｇ／ｍ２ ｄ１，８．ＩＦ（） １． ２ ｇ／ｍ２ ｄ，～４． ＤＤＰ ８０ｍｇ／ｍ２ｄ１。２疗程化疗后可手术或放疗，然后再行ＮＰ方案２个疗程，ＮＶＢ ３０ｍｇ／ｍ２ｄ１．８，ＤＤＰ ８０ｍｇ／ｍ’ ｄ１。结果部分缓解１９例，有效率６３．３％（１９／３０）。９例在诱导化疗后进行手术。全组中位生存期是１０．５个月（３～ ２３个月），１年生存率为７６．５％（１３／１７）。主要不良反应为脱发、骨髓抑制、恶心、呕吐、静脉炎、周围神经麻木、轻度 的肝功能损害。结论以长春瑞宾为主的联合化疗方案（ＮＩＰ）治疗Ⅲ期非小细胞肺癌有较高的疗效，毒性可以耐 受。
Objective To evaluate the efficacy and side effects of vinorelbine-based combination chemotherapy in the treatment of stage Ⅲ non-small cell lung cancer. Method 3. Cases of newly diagnosed patients were cytologically or pathologically confirmed stage Ⅲ non-small cell lung cancer, using NIP program: NVB 25 mg / m2 d1,8. IF () 1. 2 g / m2 d, ~ 4. DDP 80mg / m2d1.2 course of chemotherapy after surgery or radiotherapy, and then re-NP regimen 2 courses, NVB 30mg / m2d1.8, DDP 80mg / m ’d1. The results of partial remission in 19 cases, the effective rate was 63.3% (19/30). Nine patients underwent chemotherapy after chemotherapy. The median overall survival was 10.5 months (3-23 months) and 1-year survival was 76.5% (13/17). The main adverse reactions were alopecia, myelosuppression, nausea, vomiting, phlebitis, peripheral nerve numbness, and mild liver dysfunction. Conclusion The combination of vinorelbine-based combination chemotherapy (NIP) for the treatment of stage Ⅲ non-small cell lung cancer has a higher efficacy, toxicity can be tolerated.